Advances in multimodality therapy have included the use of a class of chemotherapy drugs referred to as folate antimetabolites. The most common drug used in this class is pemetrexed, which is most effective when combined with platinum-based agents, such as cisplatinum. These drugs may be given ...
Platinum chemotherapyNGSHomologous recombination deficiency (HRD) is a molecular biomarker for administrating PARP inhibitor (PARPi) or platinum-based (Pt) chemotherapy. The most well-studied mechanism of causing HRD is pathogenicBRCA1/2mutations, while HRD phenotype is also present in patients without...
Journal of Translational Medicine(2024) Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis Sangwon Shin Jimin Moon Seunghwan Shin BMC Cancer(2024) Biomarker discovery with quantum neural networks: a case-study in CT...
One hundred and twelve (56.6%) patients received adjuvant chemotherapy (cisplatinum-based doublets) after operation, and among these patients, the mean cycle of chemotherapy is 3.91 (from 1 to 4). In patients with sensitive mutations, none of them received targeted therapy after operation since ...
chemotherapy, or radiation therapy, as well as combinations of these treatments. Targeted therapies and immunotherapy treatments are becoming more common, as well. The decision about which treatments will be appropriate for a given individual must take into account the location and extent of the tumor...
chemotherapy, or radiation therapy, as well as combinations of these treatments. Targeted therapies and immunotherapy treatments are becoming more common, as well. The decision about which treatments will be appropriate for a given individual must take into account the location and extent of the tumor...
chemotherapy, or radiation therapy, as well as combinations of these treatments. Targeted therapies and immunotherapy treatments are becoming more common, as well. The decision about which treatments will be appropriate for a given individual must take into account the location and extent of the tumor...
aResults from two, multicenter, placebo-controlled, randomized, Phase 3 trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of TARCEVA with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and ...
Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients undergoing neoadjuvant chemotherapy Marta Sevieri Francesco Andreata Serena Mazzucchelli Journal of Nanobiotechnology(2024) ...
Ovarian cancer may be treated with radiation therapy, surgery, chemotherapy, or a combination. To evaluate the contribution of radiation therapy to patient... Bush,R S - 《Radiology》 被引量: 16发表: 1984年 The outcomes of radiotherapy in patients with ovarian carcinoma Relapses of ovarian canc...